Patients ask this expecting a country name. The more useful answer is an explanation of why the differences between countries are mostly legal rather than clinical — and what that means for how you choose.
Why the Question Hides the Real Distinction
"Stem cell therapy" covers two very different things. One is a set of established hospital procedures with decades of outcome data. The other is a broad group of investigational cell protocols still being studied. The two are regulated differently, delivered differently and evidenced differently, and any country comparison that blends them will mislead.
Separate them and the map becomes readable.
Established Therapies: Available Almost Everywhere
Haematopoietic stem cell transplantation for blood cancers and blood disorders, limbal stem cell grafting for certain corneal injuries, and a small group of approved cell and gene therapies are approved in most developed health systems. For these, there is no meaningful sense in which one country is "best".
What varies is centre volume and experience. Transplant outcomes correlate with how many procedures a unit performs and how well it manages complications — a hospital-level variable, not a national one. If you need one of these treatments, you are choosing a transplant centre, and usually within your own health system.
Investigational Therapies: A Regulatory Map
For mesenchymal and other cultured cell protocols, the difference between countries is what is legally permitted outside a trial.
- Japan and South Korea operate conditional or expedited approval pathways for certain regenerative products, allowing earlier access with continued data collection.
- Thailand, Panama and Mexico permit supervised treatment through defined regulatory routes in licensed facilities.
- The United States, United Kingdom, Australia and most of the European Union classify these preparations as medicinal products requiring formal approval, which in practice confines most treatment to clinical trials.
This is why patients from Australia, Singapore and Europe travel: not because the science is different abroad, but because the permission is.
Availability Is Not a Clinical Verdict
It is tempting to read permissive regulation as confidence and restrictive regulation as caution justified by failure. Neither reading holds. Regulators are making judgements about the burden of proof required before routine use, and reasonable systems have landed in different places on that question.
The practical consequence is that a permissive jurisdiction contains both rigorous programmes and poor ones. The country tells you what is allowed; it tells you nothing about the clinic in front of you.
What to Compare Instead of Countries
Ask every provider, in any jurisdiction, the same set of questions: who is the registered physician responsible for your care, which laboratory processes the cells and what release testing is documented, what cell source and dose are proposed, what the written plan includes and excludes, and what follow-up exists after you fly home.
Two further considerations matter when treating abroad: whether your discharge documentation is detailed enough for your own physician to act on, and what recourse exists if something goes wrong. Our medical travel checklist covers both.
Where Thailand Sits
Thailand combines a defined regulatory route for supervised cell therapy with established hospital infrastructure, concentrated laboratory capacity in Bangkok, and strong international flight connections for patients from Australia, Singapore and Europe. That combination is why it appears on most shortlists.
It is not a guarantee of quality, and it should not be treated as one. Our guide for international patients explains how the framework works, and how to judge a Thai provider sets out the criteria to apply.
Ask Us the Same Questions You Would Ask Anyone Else
Our medical team will answer in writing, and will tell you if treatment is not appropriate for your case. Learn more about MRC Healthcare or arrange a consultation.
Schedule a Consultation
